These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 37376442)
1. Immunogenicity and Blocking Efficacy of Norovirus GII.4 Recombinant P Protein Vaccine. Yu Z; Shao Q; Xu Z; Chen C; Li M; Jiang Y; Cheng D Vaccines (Basel); 2023 Jun; 11(6):. PubMed ID: 37376442 [TBL] [Abstract][Full Text] [Related]
2. Linear epitope binding antibodies against GII.3 Norovirus exhibit no histo-blood group antigens (HBGAs) blocking effects. Ma S; Zhang F; Zheng L; Liu J; Ma J; Chen X; Yang Z; Wang W; Li L; Wang M; Huo Y Virus Genes; 2019 Jun; 55(3):280-289. PubMed ID: 30725444 [TBL] [Abstract][Full Text] [Related]
3. Receptor profile and immunogenicity of the non-epidemic norovirus GII.8 variant. Gao J; Xue L; Liang Y; Wang L; He F; Meng L; Cai W; Zhang J; Wang J; Ye Q; Wu S; Gu Q; Wu Q Virus Res; 2021 Dec; 306():198603. PubMed ID: 34662679 [TBL] [Abstract][Full Text] [Related]
4. Biological and immunological characterization of norovirus major capsid proteins from three different genotypes. Huo Y; Wan X; Ling T; Shen S Microb Pathog; 2016 Jan; 90():78-83. PubMed ID: 26616166 [TBL] [Abstract][Full Text] [Related]
5. Characterization of virus-like particles derived from a GII.3 norovirus strain distantly related with current dominating strains. Huo Y; Chen X; Zheng L; Huo J; Zhang S; Wang M; Wang Y Virus Genes; 2016 Oct; 52(5):613-9. PubMed ID: 27234312 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and protective potency of Norovirus GII.17 virus-like particle-based vaccine. Chen W; Kang T; Yuan R; Shao C; Jing S Biotechnol Lett; 2020 Jul; 42(7):1211-1218. PubMed ID: 32088791 [TBL] [Abstract][Full Text] [Related]
7. Antibodies against Lewis antigens inhibit the binding of human norovirus GII.4 virus-like particles to saliva but not to intestinal Caco-2 cells. Carmona-Vicente N; Allen DJ; Rodríguez-Díaz J; Iturriza-Gómara M; Buesa J Virol J; 2016 May; 13():82. PubMed ID: 27206610 [TBL] [Abstract][Full Text] [Related]
8. Human Sera Collected between 1979 and 2010 Possess Blocking-Antibody Titers to Pandemic GII.4 Noroviruses Isolated over Three Decades. Sharma S; Carlsson B; Czakó R; Vene S; Haglund M; Ludvigsson J; Larson G; Hammarström L; Sosnovtsev SV; Atmar RL; Green KY; Estes MK; Svensson L J Virol; 2017 Jul; 91(14):. PubMed ID: 28468886 [TBL] [Abstract][Full Text] [Related]
9. Functional and structural characterization of Norovirus GII.6 in recognizing histo-blood group antigens. Cong X; Li HB; Sun XM; Qi JX; Zhang Q; Duan ZJ; Xu Y; Liu WL Virol Sin; 2023 Feb; 38(1):56-65. PubMed ID: 36216242 [TBL] [Abstract][Full Text] [Related]
10. A DNA vaccine against GII.4 human norovirus VP1 induces blocking antibody production and T cell responses. Kim NE; Kim MJ; Park BJ; Kwon JW; Lee JM; Park JH; Song YJ Vaccine; 2024 Feb; 42(6):1392-1400. PubMed ID: 38320930 [TBL] [Abstract][Full Text] [Related]
11. Genomic and biological characterization of a pandemic norovirus variant GII.4 Sydney 2012. Ge L; Chen X; Liu J; Zheng L; Chen C; Luo S; Guo P; Kong J; Song Y; Huo Y Virus Genes; 2020 Apr; 56(2):174-181. PubMed ID: 31912284 [TBL] [Abstract][Full Text] [Related]
12. A split NanoLuc complementation-based human norovirus-like particle entry assay facilitates evaluation of anti-norovirus antibodies in live cells. Qiao W; Wang S; Zhang C; Huang Z Antiviral Res; 2022 Jan; 197():105231. PubMed ID: 34965447 [TBL] [Abstract][Full Text] [Related]
13. Expression and characterization of the major capsid protein derived from a GII.6 norovirus strain isolated in China. Huo Y; Zheng L; Chen X; Ge L; Wang Y Microb Pathog; 2017 Apr; 105():131-137. PubMed ID: 28219831 [TBL] [Abstract][Full Text] [Related]
14. Structural analysis of determinants of histo-blood group antigen binding specificity in genogroup I noroviruses. Shanker S; Czako R; Sankaran B; Atmar RL; Estes MK; Prasad BV J Virol; 2014 Jun; 88(11):6168-80. PubMed ID: 24648450 [TBL] [Abstract][Full Text] [Related]
15. Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. Debbink K; Donaldson EF; Lindesmith LC; Baric RS J Virol; 2012 Jan; 86(2):1214-26. PubMed ID: 22090110 [TBL] [Abstract][Full Text] [Related]
16. Replication of Human Norovirus RNA in Mammalian Cells Reveals Lack of Interferon Response. Qu L; Murakami K; Broughman JR; Lay MK; Guix S; Tenge VR; Atmar RL; Estes MK J Virol; 2016 Oct; 90(19):8906-23. PubMed ID: 27466422 [TBL] [Abstract][Full Text] [Related]
17. Evolution of the interactions between GII.4 noroviruses and histo-blood group antigens: Insights from experimental and computational studies. Liang Y; Wang WB; Zhang J; Hou JW; Tang F; Zhang XF; Du LF; Su JG; Li QM PLoS Pathog; 2021 Jul; 17(7):e1009745. PubMed ID: 34252166 [TBL] [Abstract][Full Text] [Related]
18. Human Norovirus Neutralized by a Monoclonal Antibody Targeting the Histo-Blood Group Antigen Pocket. Koromyslova AD; Morozov VA; Hefele L; Hansman GS J Virol; 2019 Mar; 93(5):. PubMed ID: 30541855 [TBL] [Abstract][Full Text] [Related]
19. A bivalent virus-like particle based vaccine induces a balanced antibody response against both enterovirus 71 and norovirus in mice. Wang X; Ku Z; Dai W; Chen T; Ye X; Zhang C; Zhang Y; Liu Q; Jin X; Huang Z Vaccine; 2015 Oct; 33(43):5779-5785. PubMed ID: 26424606 [TBL] [Abstract][Full Text] [Related]
20. Chimeric VLPs with GII.3 P2 domain in a backbone of GII.4 VP1 confers novel HBGA binding ability. Huo Y; Wang W; Ling T; Wan X; Ding L; Shen S; Huo J; Zhang S; Wang M; Wang Y; Liu Y Virus Res; 2016 Sep; 224():1-5. PubMed ID: 27521750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]